Repligen Seeks To Block Launch Of Bristol-Myers Drug

Law360, New York (January 6, 2006, 12:00 AM EST) -- A Massachusetts biotech company has rekindled its battle with Bristol-Myers Squibb over the patent for a new arthritis drug, which the global pharmaceutical company plans to launch next month.

The lawsuit, filed by Repligen Corp., marks a change in tactic for the biotech company, which previously sued Bristol-Myers over ownership rights to a different patent for the same technology.

Repligen lost those legal bids. But now the company is trying a new approach, suing Bristol-Myers for infringement of another patent, issued in 2004 to the same...
To view the full article, register now.